ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 239,99
0,17%
Dow Jones
39 908,00
0,88%
DAX
18 869,36
0,78%
Brent Oil
82,715
0,20%
Bitcoin
65 946,07
7,13%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Viatris Inc (VTRS)

  7. Viatris Inc (VTRS) Actualités

VTRS

Viatris (VTRS)

Viatris Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:VTRS
DateHeureSourceTitreSymboleSociété
09/05/202413h47IH Market NewsU.S. Index Futures Dip, Bank of England Holds Interest Rates at 5.25%NASDAQ:VTRSViatris Inc
09/05/202413h44Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VTRSViatris Inc
09/05/202412h59PR Newswire (US)Viatris Reports Strong First Quarter 2024 Financial Results and Reaffirms 2024 Financial Guidance RangesNASDAQ:VTRSViatris Inc
02/05/202423h00PR Newswire (US)Viatris to Participate in the BofA Securities 2024 Health Care ConferenceNASDAQ:VTRSViatris Inc
01/05/202412h59PR Newswire (US)Viatris Expands its Wellbeing Program with the Launch of Unmind, a Leading Workplace Resource Focused on Mental HealthNASDAQ:VTRSViatris Inc
16/04/202422h30PR Newswire (US)Viatris to Report First Quarter 2024 Financial Results on May 9, 2024NASDAQ:VTRSViatris Inc
15/04/202414h00PR Newswire (US)Viatris Appoints Corinne Le Goff as Chief Commercial OfficerNASDAQ:VTRSViatris Inc
15/04/202412h59PR Newswire (Canada)Viatris annonce le lancement de la première version générique bioéquivalente du Copaxone [MD] 20 mg/mL au CanadaNASDAQ:VTRSViatris Inc
15/04/202412h59PR Newswire (Canada)Viatris Announces Launch of First Bioequivalent Generic Version of Copaxone® 20 mg/mL Once-Daily in CanadaNASDAQ:VTRSViatris Inc
01/04/202412h59PR Newswire (US)Viatris Announces the Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution) 0.75% in the United StatesNASDAQ:VTRSViatris Inc
27/03/202411h59PR Newswire (US)Viatris Hosts R&D Event Focusing on its Collaboration with Idorsia, Phase 3 Assets Selatogrel and Cenerimod and Key Elements of its PipelineNASDAQ:VTRSViatris Inc
06/03/202402h29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VTRSViatris Inc
06/03/202401h26Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:VTRSViatris Inc
05/03/202400h11Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VTRSViatris Inc
28/02/202412h30PR Newswire (US)Viatris Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial GuidanceNASDAQ:VTRSViatris Inc
28/02/202407h00PR Newswire (US)Viatris and Idorsia Enter Into Significant Global Research and Development CollaborationNASDAQ:VTRSViatris Inc
05/02/202412h59PR Newswire (US)Viatris to Announce Fourth Quarter and Full-Year 2023 Financial ResultsNASDAQ:VTRSViatris Inc
30/01/202422h40Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:VTRSViatris Inc
19/01/202412h56PR Newswire (US)Viatris recognised as a Top Employer 2024 in the UK for the second consecutive yearNASDAQ:VTRSViatris Inc
21/12/202322h05PR Newswire (US)Viatris to Participate in 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:VTRSViatris Inc
15/12/202322h45PR Newswire (US)Viatris Continues its Preparations for Phase 2 of its Strategic Plan by Announcing the Appointment of Theodora "Doretta" Mistras as Chief Financial Officer, Effective March 1, 2024, and Philippe Martin as Chief R&D OfficerNASDAQ:VTRSViatris Inc
15/12/202322h05PR Newswire (US)Viatris Shareholders Re-elect All Nominated Directors and Approve All Voting Matters at Annual Meeting of ShareholdersNASDAQ:VTRSViatris Inc
24/11/202322h30Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:VTRSViatris Inc
14/11/202314h00PR Newswire (US)Viatris to Participate in the Jefferies London Healthcare ConferenceNASDAQ:VTRSViatris Inc
13/11/202314h00PR Newswire (US)Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI® (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)NASDAQ:VTRSViatris Inc
07/11/202322h02PR Newswire (US)Viatris Reports Strong Financial and Operational Results for the Third Quarter 2023 and Reaffirms Full-Year 2023 Adjusted EBITDA and Free Cash Flow Guidance Ranges[1]NASDAQ:VTRSViatris Inc
03/11/202321h36Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:VTRSViatris Inc
03/11/202321h31Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:VTRSViatris Inc
30/10/202314h00PR Newswire (US)Viatris to Host Webinar: The Power of Partnership to Address Antimicrobial ResistanceNASDAQ:VTRSViatris Inc
24/10/202322h30Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:VTRSViatris Inc
 Showing the most relevant articles for your search:NASDAQ:VTRS

Dernières Valeurs Consultées

LSE
ZU96
Citi Fun 24
BOV
PETRR302
PETRR302 Ex:27,45
BIT
F15449
Vontobel Financial Produ...
BOV
BLUR11
Blue Recebiveis Imobilia...
BIT
P1DD87
BNP Paribas Issuance
BIT
P44571
Bnp Paribas Issuance
LSE
MERC
Mercia Asset Management
HUOB
XETAUSDT
XANA
COIN
WPXKRW
WalletPlusX
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés